Treating non-alcoholic fatty liver disease accompanied by hyperlipidemia with Xuezhikang Capsule

AIM: To study the curative effect of Xuezhikang Capsule on non-alcoholic fatty liver disease accompanied by hyperlipidemia. METHODS: Small dosage of Xuezhikang Capsules had been administrated to the patients with non-alcoholic fatty liver disease accompanied by hyperlipidemia for 6 months. 32 healthy people had been chosen as control group at the same time. At the time points of before and after curing, body weight index. Type B ultrasonic, liver function, serum lipids, serum glucose and insulin levels had been tested. The McAuley index and the insulin resistance index of the homeostasis model assessment had been taken to evaluate insulin resistance. Liver biopsy had been conducted in some of the patients to compare the tissue changes before and after curing. RESULTS: After being treated with Xuezhikang Capsule, levels of insulin resistance serum lipids and ALT/AST in the patients with non-alcoliolic fatty liver disease had gone downward markedly. The histological observation in some of the patients had improved. No toxicity had been found. CONCLUSION: It is safe and potent to take the small dosage of Xuezhikang Capsule to cure the patients with non-alcoholic fatty liver disease accompanied by hyperlipidemia.